Biomarkers, Neurodevelopment and Preterm Infants



Status:Recruiting
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:Any
Updated:1/13/2018
Start Date:April 2015
End Date:December 2020
Contact:Mamta Fuloria, MD
Email:mfuloria@montefiore.org
Phone:718-904-4105

Use our guide to learn which trials are right for you!

Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants

Approximately 2% of neonates in the US are born very preterm. Preterm births are associated
with impaired cognitive, language and motor function, and increased risk for autism spectrum
disorders. Epidemiological studies indicate a dose-response relationship between gestational
age at delivery and cognitive impairments, with the most immature of newborns being the most
susceptible to developmental delays. Sensitive and reproducible biomarkers of long-term
neurocognitive impairments are currently lacking. The investigators seek to identify
epigenetic markers that mediate the relationship between adverse prematurity-related
exposures and neurocognitive impairments. The overarching hypothesis of this proposal is that
DNA methylation profiles of CD34+ hematopoetic progenitor and stem cells from very preterm
infants can be used as a risk-stratifying biomarker for predicting neurocognitive impairment
in childhood.


Inclusion Criteria:

- <32 weeks‟ gestation

- Born at Weiler Division of Montefiore

Exclusion Criteria:

- Intraventricular hemorrhage

- Chromosomal abnormalities

- Congenital viral conditions
We found this trial at
1
site
Bronx, New York
Phone: 718-904-4105
?
mi
from
Bronx, NY
Click here to add this to my saved trials